- Home
- SLN vs ZH Comparison
SLN vs ZH Comparison
Compare SLN & ZH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SLN
- ZH
- Stock Information
- Founded
- SLN 1994
- ZH 2011
- Country
- SLN United Kingdom
- ZH China
- Employees
- SLN N/A
- ZH N/A
- Industry
- SLN Biotechnology: Pharmaceutical Preparations
- ZH Business Services
- Sector
- SLN Health Care
- ZH Consumer Discretionary
- Exchange
- SLN Nasdaq
- ZH Nasdaq
- Market Cap
- SLN 345.3M
- ZH 397.3M
- IPO Year
- SLN N/A
- ZH 2021
- Fundamental
- Price
- SLN $6.67
- ZH $3.69
- Analyst Decision
- SLN Buy
- ZH Strong Buy
- Analyst Count
- SLN 6
- ZH 1
- Target Price
- SLN $39.67
- ZH $4.70
- AVG Volume (30 Days)
- SLN 212.8K
- ZH 182.4K
- Earning Date
- SLN 11-06-2025
- ZH 11-25-2025
- Dividend Yield
- SLN N/A
- ZH N/A
- EPS Growth
- SLN N/A
- ZH N/A
- EPS
- SLN N/A
- ZH 0.17
- Revenue
- SLN $25,830,000.00
- ZH $416,437,241.00
- Revenue This Year
- SLN N/A
- ZH N/A
- Revenue Next Year
- SLN N/A
- ZH $6.47
- P/E Ratio
- SLN N/A
- ZH $21.75
- Revenue Growth
- SLN 40.39
- ZH N/A
- 52 Week Low
- SLN $1.97
- ZH $3.19
- 52 Week High
- SLN $8.88
- ZH $6.32
- Technical
- Relative Strength Index (RSI)
- SLN 55.39
- ZH 28.64
- Support Level
- SLN $5.91
- ZH $3.48
- Resistance Level
- SLN $6.62
- ZH $4.14
- Average True Range (ATR)
- SLN 0.51
- ZH 0.16
- MACD
- SLN -0.05
- ZH -0.02
- Stochastic Oscillator
- SLN 81.25
- ZH 24.70
About SLN Silence Therapeutics Plc American Depository Share
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.
About ZH Zhihu Inc. (every two of each representing one ordinary share)
Zhihu Inc is predominantly engaged in the operation of one online content community and monetizes through paid membership services, advertising services, content-commerce solutions services, and vocational training in China. It generates revenues from Advertising services, Paid membership services, Content-commerce solutions, and Others. It derives all its revenues within China.